Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HS-20093 versus investigator's choice chemotherapy in previously treated advanced esophageal squamous cell carcinoma
CTR20262107Phase 3Active
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risvutatug rezetecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Hansoh Pharmaceutical Group. Started Jun 2026; status: active.
02
Drugs
risvutatug rezetecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20262107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262107.